Genflow Biosciences Advances SIRT6 Variant Patent Application

Genflow Biosciences PLC (LSE:GENF)(OTCQB:GENFF), an emerging leader in longevity research, has announced significant progress in its patent application for SIRT6 variants. The European patent application (EP 22 808 414.1), filed on May 13, 2022, by the University of Rochester, The Trustees of Columbia University in the City of New York, and the Albert Einstein College of Medicine, has successfully cleared the Supplementary European Search Report without further questions from the European Patent Office (EPO). This milestone marks a crucial step in securing protection for SIRT6 variants, a promising innovation in age-related disease therapeutics.

The SIRT6 gene/protein plays a critical role in DNA repair, metabolism, and longevity. The successful progression of the patent application allows Genflow Biosciences to advance to the national phase of the patent process, a critical stage in securing market-specific protections across Europe. This progress strengthens the company's position in SIRT6-based therapeutics and accelerates its mission to develop effective treatments for age-related diseases.

Genflow Biosciences remains focused on advancing its longevity-focused therapeutic pipeline and will continue to update stakeholders as the patent application progresses. Dr. Eric Leire, CEO of Genflow, commented: "This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants. This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases."



The successful progression of the SIRT6 variant patent application has significant implications for the competitive landscape of age-related disease therapeutics and the valuation and investment attractiveness of Genflow Biosciences. The intellectual property protection secured by this patent application provides Genflow Biosciences with a competitive edge in the market, offering market exclusivity, a strengthened position in SIRT6-based therapeutics, potential licensing revenue, and enhanced reputation and credibility.

Considering the potential market size and growth prospects of age-related disease therapeutics, this patent application advancement influences the valuation and investment attractiveness of Genflow Biosciences. The global market for age-related disease therapeutics is expected to grow at a CAGR of approximately 7.5% during the forecast period (2021-2028), reaching USD 125.2 billion by 2028. This growth is driven by an aging population and increasing prevalence of age-related diseases.

The advancement of Genflow Biosciences' patent application for SIRT6 variants positively influences the company's valuation and investment attractiveness by strengthening its intellectual property position, providing a competitive advantage, and opening up new revenue streams in the growing age-related disease therapeutics market. The successful progression of the patent application increases the attractiveness of Genflow as an investment opportunity, making it an appealing target for investors seeking exposure to the growing age-related disease therapeutics market.

In conclusion, the successful progression of Genflow Biosciences' patent application for SIRT6 variants is a significant milestone in the company's mission to develop effective treatments for age-related diseases. This advancement provides the company with a competitive advantage in the market, enhances its valuation and investment attractiveness, and brings it one step closer to commercializing its innovative SIRT6-based therapeutics. As the company continues to update stakeholders on the progress of the patent application, investors should closely monitor Genflow Biosciences' developments in the age-related disease therapeutics market.